RxDoctor Payments Data

Jill Olek, MD

Family Medicine · Americus, GANPI 1154632685

Payments from drug & device makers

$7,972in general payments, 2019–2025

Across 449 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$969
  • Novo Nordisk$730
  • Boehringer Ingelheim$507
  • Amgen$495
  • AbbVie$457
  • Lilly USA, LLC$401
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,972 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$157,622
Medicare patients
324
Services billed
2,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide142$170,058
EliquisApixaban160$157,270
OzempicSemaglutide95$128,012
XareltoRivaroxaban122$115,394
TrulicityDulaglutide81$105,302
JardianceEmpagliflozin116$91,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$62,384
Tresiba Flextouch U-200Insulin Degludec80$57,654
JanuviaSitagliptin Phosphate52$53,414
LinzessLinaclotide63$48,211
RybelsusSemaglutide27$45,447
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$40,690
VraylarCariprazine Hcl28$39,105
TradjentaLinagliptin46$32,514
GlyxambiEmpagliflozin/Linagliptin24$30,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$401$275,359223 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr, Synjardy Xr$507$220,026296 claims
Novo NordiskOzempic, Rybelsus$730$173,459122 claims
PfizerEliquis$389$157,270160 claims
Johnson & JohnsonXarelto$350$115,394122 claims
AbbVieLinzess, Vraylar, Creon$457$113,451106 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Anoro Ellipta$969$97,642225 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$388$78,548136 claims
MerckJanuvia, Janumet Xr$94$70,74771 claims
Astellas Pharma US IncMyrbetriq$158$23,87623 claims
NovartisEntresto$237$23,51521 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$326$18,87711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Americus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →